Direkt zum Inhalt
Merck

A8978

Sigma-Aldrich

Anti-Beta (β)-Amyloid antibody

mouse monoclonal, BAM90.1

Synonym(e):

Anti-Aβ

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

25 μL
€ 165,00
200 μL
€ 457,00

€ 165,00


Check Cart for Availability

Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
25 μL
€ 165,00
200 μL
€ 457,00

About This Item

MDL-Nummer:
UNSPSC-Code:
12352203
NACRES:
NA.41

€ 165,00


Check Cart for Availability

Bulk-Bestellung anfordern

Produktbezeichnung

Anti-β-Amyloid (13-28) antibody, Mouse monoclonal, clone BAM90.1, purified from hybridoma cell culture

Biologische Quelle

mouse

Qualitätsniveau

Konjugat

unconjugated

Antikörperform

purified immunoglobulin

Antikörper-Produkttyp

primary antibodies

Klon

BAM90.1, monoclonal

Form

buffered aqueous solution

Speziesreaktivität

human

Verpackung

antibody small pack of 25 μL

Konzentration

~2 mg/mL

Methode(n)

enzyme immunoassay: 0.2-0.4 μg/mL using amyloid β-protein
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

Isotyp

IgG1

UniProt-Hinterlegungsnummer

Versandbedingung

dry ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... APP(351)

Allgemeine Beschreibung

Amyloids are insoluble protein aggregates consisting of misfolded proteins and peptides. Amyloid deposition are associated with multiple neurodegenerative disorders.
The β-amyloid precursor protein (APP) is cleaved sequentially by the proteolytic enzymes β-secretase (BACE1) and γ-secretase to produce β-amyloid (Aβ) peptides with the Aβ1-42 and the Aβ1-40 forms being the most prevalent. Secreted Aβ peptides are degraded either via a re-uptake mechanism followed by endosomal degradation, or by an extracellular insulin degrading enzyme. Extracellular accumulation of Aβ leads to the formation of aggregates, fibrils and eventually amyloid deposits called neuritic plaques, which is the hallmark of Alzheimer′s disease (AD).
Monoclonal Anti β-Amyloid [13-28] recognizes the β-Amyloid peptide. The antibody epitope resides within amino acids 20-23.

Anwendung

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunohistochemistry (1 paper)
Mouse Monoclonal Anti-β-Amyloid (13-28) antibody can be used for immunoblotting assays at 1:5,000. The antibody can also be used for IHC, immunoprecipitation,fluorescence infrared spectroscopy and enzyme immunoassays (02-0.4μg/ml).

Physikalische Form

Filtered solution in 0.01 M phosphate buffered saline, pH 7.4.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Julia Stockmann et al.
Alzheimer's research & therapy, 12(1), 169-169 (2020-12-29)
We evaluated Aβ misfolding in combination with Aβ42/40 ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer's disease (AD) in individuals with subjective cognitive decline (SCD). Baseline plasma samples (n = 203)
Andreas Nabers et al.
EMBO molecular medicine, 10(5) (2018-04-08)
Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid
Amyloid-beta-secondary structure distribution in cerebrospinal fluid and blood measured by an immuno-infrared-sensor: A biomarker candidate for Alzheimer?s disease
Nabers A, et al.
Analytical Chemistry, 88, 2755-2762 (2016)
Amyloid blood biomarker detects Alzheimer's disease
Nabers A, et al.
EMBO Molecular Medicine, {e8763-{e8763 (2018)
M Medecigo et al.
Journal of neuroimmunology, 223(1-2), 104-114 (2010-05-11)
Anti-amyloid immunotherapy has been proposed as an appropriate therapeutic approach for Alzheimer's disease (AD). Significant efforts have been made towards the generation and assessment of antibody-based reagents capable of preventing and clearing amyloid aggregates as well as preventing their synaptotoxic

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.